Zurcher Kantonalbank (Zurich Cantonalbank) Inhibrx, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

  • $30.1 Billion
  • Q2 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 25, 2024
BUY
$32.76 - $39.56 $55,593 - $67,133
1,697 Added 55.49%
4,755 $166,000
Q3 2023

Oct 25, 2023
SELL
$15.75 - $26.31 $15 - $26
-1 Reduced 0.03%
3,058 $56,000
Q1 2023

May 08, 2023
SELL
$18.45 - $27.14 $10,258 - $15,089
-556 Reduced 15.38%
3,059 $57,000
Q4 2022

Feb 01, 2023
SELL
$20.18 - $33.33 $1,796 - $2,966
-89 Reduced 2.4%
3,615 $89,000
Q3 2022

Nov 09, 2022
BUY
$11.58 - $24.73 $34,612 - $73,917
2,989 Added 418.04%
3,704 $66,000
Q1 2022

Apr 21, 2022
BUY
$19.89 - $43.18 $14,221 - $30,873
715 New
715 $16,000

Others Institutions Holding INBX

# of Institutions
2
Shares Held
25.3K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email